The first priority in acute canine CHF is oxygen supplementation and minimal-stress handling before any examination or diagnostics. A dog presenting with significant dyspnea should receive supplementary oxygen and, if needed, light sedation before physical examination or diagnostic testing, because stress alone can be fatal in a severely dyspneic patient. In Practice
Treatment is initiated on a working diagnosis, not a definitive one. Identifying a cardiac cause for respiratory distress is more important than establishing the precise underlying cardiac disease in the acute phase. In Practice The clinical signs of CHF overlap with non-cardiac causes of respiratory compromise, so differentiating cardiac from non-cardiac disease is the central diagnostic challenge in the emergency setting. In Practice
Furosemide is the cornerstone of acute decompensation management. The acute intravenous dose is 2 mg/kg IV. Journal of the… Once the patient is stable enough for oral medication, furosemide is continued at 2.3 mg/kg PO q12h. Journal of the…
Afterload reduction and neurohormonal blockade are added once the patient tolerates oral medications. Enalapril is initiated at 0.4 mg/kg PO q12h. Journal of the… Spironolactone, an aldosterone antagonist, is added at 1.5 mg/kg PO q12h. Journal of the… The broader framework for heart failure management targets preload and afterload reduction via diuretics and vasodilators, improved cardiac performance via positive inotropes and antiarrhythmics when indicated, and neurohormonal modulation via ACE inhibitors, aldosterone antagonists, and beta-blockers. MSD Vet Manuals
Dietary modification is initiated concurrently with pharmacologic stabilization. High-sodium food and treats should be avoided, and transition to a low-sodium diet is recommended. Journal of the…
Monitoring and follow-up are structured around renal function and cardiac reassessment. A renal panel is recommended within 1–2 weeks of initiating therapy, given the hemodynamic effects of diuresis and ACE inhibition. Echocardiography is recommended at 3 months. Ongoing monitoring targets persistent cough, tachypnea, dyspnea, exercise intolerance, and syncope. Journal of the…
If anesthesia is required for any concurrent procedure, it must be deferred until the patient is stabilized. Cardiac disease should be treated first, with anesthesia rescheduled after 2–4 weeks of therapy. AAHA Clinical G…
| Drug | Dose / Route / Frequency | Role | Key Caveat |
|---|---|---|---|
| Furosemide | 2 mg/kg IV (acute); 2.3 mg/kg PO q12h (maintenance) | Preload reduction / diuresis | Renal panel within 1–2 weeks Journal of the… |
| Enalapril | 0.4 mg/kg PO q12h | ACE inhibition / afterload reduction | Monitor renal function Journal of the… |
| Spironolactone | 1.5 mg/kg PO q12h | Aldosterone antagonism | Initiated with enalapril Journal of the… |
| Clopidogrel | 2.3 mg/kg PO q24h | Antithrombotic | Initiated at same time as other oral medications Journal of the… |
Would you like the specific approach to differentiating cardiac from non-cardiac respiratory distress at the point of triage?